TP-04 is under clinical development by Tarsus Pharmaceuticals and currently in Phase I for Rosacea. According to GlobalData, Phase I drugs for Rosacea have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TP-04’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TP-04 overview

TP-04 is under development for the treatment of rosacea.

Tarsus Pharmaceuticals overview

Tarsus Pharmaceuticals is a biopharmaceutical company that is involved in development and commercialization of therapeutics related to eye care. It is developing novel therapeutics for treatment of blepharitis which is caused by the infestation of Demodex mites. The company having the product pipeline for Meibomian Gland Disease, Rosacea, Lyme Disease and Malaria. The company is headquartered in Irvine, California, the US.

For a complete picture of TP-04’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.